Johnson & Johnson announced a binding arrangement with the White House under which the company will offer select branded medicines at discounted rates through a new direct-to-patient platform, TrumpRx.gov, and align Medicaid pricing with rates seen in other developed nations. As part of the deal, J&J has committed to extend these price concessions to an estimated 10 million Americans who currently face high out-of-pocket expenses. Company CEO Joaquin Duato emphasized that the agreement preserves J&J’s $55 billion U.S. investment plan, ensuring continued funding for two new manufacturing sites—in Pennsylvania (cell therapy) and North Carolina (drug product)—and the ongoing $2 billion biologics facility in Wilson, N.C., slated to support 5,000 skilled jobs.

Within Johnson & Johnson Vision, advanced intraocular lens (IOL) offerings—multifocal, toric and extended depth-of-focus designs—are driving strong growth as global IOL revenue is forecasted to rise from $5.97 billion in 2025 to $9.85 billion by 2033 at a 6.48% CAGR. J&J Vision holds a leading position alongside Alcon and Bausch+Lomb, with particular traction in North America’s $1.60 billion segment (38.6% of global IOL sales) and rapid expansion in Asia Pacific, which is projected to grow at 7.03% annually. The segment’s strategic focus on premium lens reimbursement and surgeon training programs aims to capture share of the fastest-growing presbyopia and toric IOL categories, both expanding above 9% annually.

In its latest 13F filing, Almanack Investment Partners reported a 29.6% rise in its Johnson & Johnson holdings, adding 2,985 shares to reach a 13,074-share position valued at $2.42 million. Other notable shifts include Signature Resources Capital Management’s 262.9% gain to 254 shares and Semmax Financial Advisors’ 55% increase, bringing its total to 203 J&J shares. Collectively, institutional and hedge fund investors now own approximately 69.6% of outstanding J&J equity, underscoring confidence in the company’s defensive pharmaceutical pipeline and sustained dividend yield of 2.5%.

Johnson & Johnson has maintained its quarterly dividend at $1.30 per share, representing a $5.20 annual payout and a 50.2% payout ratio, payable March 10 to shareholders of record February 24. For fiscal 2025, J&J reaffirmed guidance of $10.80–$10.90 in adjusted earnings per share, following reported third-quarter EPS of $2.26 on revenue of $24.02 billion. Analysts covering the stock have collectively raised price targets—Goldman Sachs to $240 and Raymond James to $209—citing resilience in immunology blockbusters like Stelara and ongoing margin expansion in medical devices despite emerging Part D rebate headwinds.